IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice.
about
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional studyIdentification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohortRelation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver diseaseThyroid disease is a favorable prognostic factor in achieving sustained virologic response in chronic hepatitis C undergoing combination therapy: A nested case control study.Predicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data.Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.Targeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatmentPerceptions of genetic testing and genomic medicine among drug users.IL28B SNP genotyping among Iranian HCV-infected patients: A preliminary report.Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotypeIL28B polymorphism as a predictor of antiviral response in chronic hepatitis C.Clinical application of high throughput molecular screening techniques for pharmacogenomics.Rs12979860 and rs8099917 single nucleotide polymorphisms of interleukin-28B gene: simultaneous genotyping in caucasian patients infected with hepatitis C virus.Tolerability and efficacy of pegylated consensus interferon-α in the treatment of chronic hepatitis C.Interleukin 28B Polymorphisms and Hepatitis C-Translating the Association into Clinical Decision MakingTranslating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection.Integrative genomics strategies to elucidate the complexity of drug response.Interferons as biomarkers and effectors: lessons learned from animal models.Safety of telaprevir for chronic hepatitis C virus infection: a meta-analysis of randomized controlled trials.Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature.The potential of signal peptide peptidase as a therapeutic target for hepatitis C.MHC class I-related chain B gene polymorphism is associated with virological response to pegylated interferon plus ribavirin therapy in patients with chronic hepatitis C infection.The reduced predictive value of interleukin 28b gene polymorphisms in a cohort of patients with thyroiditis developed during antiviral therapy for chronic hepatitis C: a preliminary study.Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children.
P2860
Q28477057-E314B31F-3391-48D5-9CD8-ED921296ADE1Q28478435-7F85350F-5DB3-412A-91A7-D0F3AB72C383Q28483964-0DFCF2B4-C4B1-4C0B-8584-9DD874D23F0DQ33909535-7ABE35BE-F6C0-4A18-B346-C42B37FBD346Q33948641-2DB60587-3EB4-44F7-B477-AD8249AAF2D6Q34008754-0662BD1E-975C-4054-A336-6FC3069C33FAQ34347862-290FB720-8CA3-4877-9B01-6AABDA64F310Q34772602-E42E39A5-CB8D-41F1-9613-3F79DC2768CCQ35540229-7F9E8D54-E780-4B1F-837B-E5CFFF8AD170Q35610571-A30FEC3A-3DD0-48D4-9D34-C81BF32A43B5Q36226495-1D2D1A39-1A8A-451A-A157-3614AB0EE4AFQ36248186-C967462F-093A-42D2-9887-042ED42BCE54Q36441517-305C8D8B-D45A-4FD3-8A6A-DD927DFEC9DBQ36478562-B392A5CD-B3C5-4B52-9D81-A0869DB58092Q37593837-F5FC008C-B9E1-431D-AC9F-BD9509E1FC29Q37613481-0A1FACE3-5E09-40D5-9EA9-ADCE1D2EF5B0Q37879701-AC002888-2E76-44A1-9CF7-88BDA46908E1Q37961088-1C18147C-95A6-491A-ACA2-1FE618A8ADC9Q37997045-55CDFBF7-4881-415A-A9FF-403EFF85EFABQ38034258-D44FB487-F5FF-40E9-9D6E-C2BCD5ED3B37Q38206573-49F88837-7BC5-42AB-8976-CE587F5B22F9Q40078310-D0F9D297-3DDA-48B9-B6D4-9CC469D4015BQ41161023-91C63DFF-3073-4198-A02D-D5132EAAD2D6Q42415913-6D0ADC28-5D81-43AD-ABA0-2B1297406644Q43035295-F9A0A245-0788-4E31-92F3-2F90798A824A
P2860
IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
IL28B in hepatitis C virus inf ...... nomics into clinical practice.
@en
IL28B in hepatitis C virus inf ...... nomics into clinical practice.
@nl
type
label
IL28B in hepatitis C virus inf ...... nomics into clinical practice.
@en
IL28B in hepatitis C virus inf ...... nomics into clinical practice.
@nl
prefLabel
IL28B in hepatitis C virus inf ...... nomics into clinical practice.
@en
IL28B in hepatitis C virus inf ...... nomics into clinical practice.
@nl
P2860
P1476
IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice
@en
P2093
David R Booth
Jacob George
P2860
P304
P356
10.1007/S00535-010-0287-4
P577
2010-07-16T00:00:00Z